The Daily Beat - November 25, 2025 📈

There were no S&P 500 earnings reactions on Monday, but we want to tell you about one of our favorite growth stories in the market.

If you were building a long-term portfolio around the future of surgical care, you’d start with two companies: Intuitive Surgical $ISRG and Globus Medical $GMED. 

One is the undisputed titan of the industry, the company that quite literally invented modern robotic surgery and continues to widen its competitive moat every single quarter. 

The other is the fastest-rising challenger in the space, assembling one of the most complete, fully integrated spine ecosystems the industry has ever seen. 

Together, they sit at the center of one of the most powerful secular growth trends in healthcare: the robotic takeover of the operating room.

ISRG is as close as you get to a MedTech monopoly. Da Vinci (their flagship product) system placements are accelerating, procedure volumes are compounding, and hospitals are standardizing around them. 

And as new platforms and clinical indications roll out, the company is expanding its total addressable market faster than analysts can update their models. This is a business with recurring revenue dominance, unmatched scale, and a decade-long growth runway. 

If robotic surgery continues to eat market share, and every data point says it will, ISRG is the biggest beneficiary.

Meanwhile, GMED is doing something rare in MedTech: building an entire surgical universe under one brand. Their Excelsius platform integrates robotics, navigation, imaging, implants, and workflow software into a single spine operating environment. 

That is the holy grail for surgeons, and it's how you win hospital conversions. It's also how you build an ecosystem that compounds for years.

 Layer on the margin expansion, record cash flow, an accelerating U.S. spine business, and real international traction, and suddenly GMED isn’t the underdog. It’s the disruptor with leverage.

The fundamentals are spectacular, the growth stories are undeniable, and last week, the market finally acknowledged it.

On October 22, Intuitive Surgical posted its best earnings reaction since 2014, ripping nearly 14% in a single session. Moves like this don't happen because investors “liked the quarter.” They occur when the market decides a long-term story just got better.

And when you look at the ISRG weekly chart, that reaction fits perfectly into a much bigger picture.

Ahead of its earnings report last month, Intuitive Surgical was at the lower bound of a prolonged accumulation pattern. 

It was a make-or-break moment for the stock...

Either the sellers would resolve the top and spark a fresh primary downtrend, or the buyers would dig in and turn it into a "not a top" pattern. 

As you can see, the latter scenario played out, and the price is on the cusp of printing fresh all-time highs.

Looking at Globus Medical, the same theme reappears, only louder.

Following a blockbuster earnings report earlier this month, Globus Medical rallied nearly 36% in a single session. This was the stock's best earnings reaction ever. 

You don’t get a move like that in a company of this quality without a structural shift in how investors value the business. 

The company didn’t just deliver good numbers... They delivered conviction, and the stock is being rerated as a result.

And just as ISRG's technicals confirm its fundamentals, GMED's technicals are confirming its fundamentals.

For years, Globus Medical has been carving out a textbook accumulation pattern, building up energy for the next primary uptrend.

And after this quarter's banger earnings report, the stock is ready to take off. 

That’s the beauty of the current setup in these stocks: the fundamentals are screaming, the charts are confirming, and the market is finally repricing both companies higher at the same time. 

This isn’t random strength. It’s the market voting loudly on the future of surgical robotics.

Happy technical Tuesday

-The Beat Team